Treatments for childhood cancers have improved to the point that 5-year survival rates are over 80 percent. However, one group has failed to benefit from these improvements, namely children who die so soon after diagnosis that they are not able to receive treatment, or who receive treatment so late in the course of their disease that it is destined to fail.
Twenty-seven percent of 50 heavily pretreated patients with stage IV breast cancer saw clinical benefit from the drug, with at least “stable disease” at 24 or more weeks after the start of treatment.
A University of Colorado Cancer Center paper published today in the journal Nature Nanotechnology details how the immune system recognizes nanoparticles, potentially paving the way to counteract or avoid this detection.
Prediction model created by "research parasites" published today in Lancet Oncology offers a more accurate prognosis for a patient's metastatic castration-resistant prostate cancer
University of Colorado Cancer Center study published in the journal Gynecologic Oncology shows that only 44 percent of patients in a large, national sample received all three components of standard-of-care treatment, most often lacking brachytherapy.
University of Colorado Cancer Center study shows that comparing cancer cell sequencing results to published reference genomes may be less accurate than comparing to healthy cell from same organism.
"After chemo, PI3K helps the cell shut down and weather the storm. Then when the chemo is gone, PI3K helps cancer stem cells start back up again," says University of Colorado Cancer Center investigator, Antonio Jimeno, MD, PhD.
New understanding stops bladder cancer's ability to stop the tumor-suppressing gene RhoDGI2, thus allowing its initial action to proceed.
University of Colorado Cancer Center investigators unpack the mechanism of investigational drug, AMPI-109, showing its inactivation of PRL-3 flips an important switch on triple-negative breast cancer.
University of Colorado Cancer Center researcher shows that women who contract malaria while pregnant may have children with an increased risk of Burkitt's lymphoma.
Nobel laureate and University of Colorado Cancer Center investigator, Thomas Cech, PhD, uses CRISPR gene editing technology and live cell, single molecule microscopy to watch in real-time, for the first time, the essential interaction between telomerase and telomeres.
University of Colorado Cancer Center study details the hospital procedures that lead to discrepancies between initial, intraoperative pathology evaluation and the results of the final, less pressured examination.
By recognizing a drug's ability to stop cancer's energy overuse, doctors may be able to determine a patient's response to a new, targeted therapy far earlier and with far more precision than watching and waiting for a tumor to shrink.
Text-mining tool developed at CU Cancer Center and published today in Bioinformatics helps researchers map connections between genes, proteins, drugs, diseases.
A University of Colorado Cancer Center study finds that three years post bone marrow transplant, the incidence of severe chronic graft-versus-host disease was 44 percent in patients who had received transplants from matched, unrelated donors (MUD) and 8 percent in patients who had received umbilical cord blood transplants (CBT).
University of Colorado Cancer Center study in Cell Reports shows role of TIP60 in allowing human colorectal cancer cells to survive at the oxygen-poor centers of tumors.
University of Colorado Cancer Center study published online in Oncogene describes mutational landscape of bladder cancer cell lines, demonstrates that alterations in these cells lines do indeed match changes in samples of human bladder cancer and shows genes and gene pathways that may be functionally involved in the ability of bladder cancer to resist therapy.
Hispanic white and non-Hispanic black cancer patients between ages 15 and 29 may be more likely than same-aged white patients to die of their disease, according to a University of Colorado Cancer Center study presented at the American Society for Clinical Oncology (ASCO) Annual Meeting 2016.
CU Cancer Center presented at ASCO 2016 finds that in Colorado patients over 50, the rate of CRC is falling at 2.5 percent per year while the rate of CRC in patients under 50 is rising at 0.8 percent per year. The increase in incidence appeared to be driven mostly by an increase in late-stage CRC in the under-50 population with an increase of 2.4 percent per year from 2003 through 2013.
At ASCO 2016: University of Colorado Cancer Center study shows that younger colorectal cancer patients are more likely to have alterations in genes involved in what is known as the Wnt signaling pathway, a system of communication that drives the growth, survival and proliferation of cancer stem cells.
Paul Bunn, Jr., MD, FASCO, distinguished professor at the University of Colorado Cancer Center and James Dudley Professor of Lung Cancer Research at the University of Colorado School of Medicine has been named the 2016 David A. Karnofsky Memorial Award and Lecture recipient, a prestigious award presented at the American Society of Clinical Oncology’s (ASCO) Annual Meeting.
A University of Colorado Cancer Center study shows that more than half of elderly metastatic colorectal cancer patients are receiving three or more treatments, increasing cost and side effects with only one-month gain in median survival.
Even in the healthcare landscape as it existed before the ACA, cancer survivors in states without expanded Medicaid were less likely to have a personal doctor and more likely to report inability to see a doctor due to cost (odds ratios 0.76 and 1.14 respectively).
University of Colorado Cancer Center study shows that some uninsured and low-income breast cancer patients do without even low-cost, high-benefit drugs.
A University of Colorado Cancer Center study recently published in the International Journal of Gynecological Cancer shows that protein cytokeratin 5 (CK5), known to be a marker of poor prognosis in breast cancer, also marks ovarian cancers likely to be resistant to the common chemotherapy cisplatin.
University of Colorado Cancer Center study shows how iron nanoparticles evade human immune system, potentially helping useful particles avoid elimination.
New ACS breast cancer screening guidelines consider anxiety associated with mammography when deciding who should be screened. A University of Colorado Cancer Center study describes a successful intervention to decrease this anxiety, lessening this barrier to screening.
The New England Journal of Medicine reports the results of a 2,259-person study conducted at 11 academic medical centers, including University of Colorado Cancer Center, showing that taking vitamin D and/or calcium supplements after the removal of pre-cancerous colorectal polyps does not reduce risk of developing polyps in the future.
A University of Colorado Cancer Center study being presented at the 16th World Conference on Lung Cancer reveals the full extent to which the CNS may be under-explored in clinical research.
A University of Colorado Cancer Center study being presented today at the 16th World Conference on Lung Cancer in Denver, Colorado sheds light on the best method to determine the threshold at which MET amplification becomes clinically relevant.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right